News & Information

Keep up with the latest from R&D Partners

Italian Pharma, Chiesi Buys Asthma Company Putting It Against Novartis

A privately owned Italian pharmacy called Chiesi Farmaceutici bought all outstanding shares and assets from the asthma-focused biotech, Atopix Therapeutics. This deal puts Chiesi against an established eosinophilic asthma market. A market which includes targeted biologics such as GlaxoSmithKline’s Nucala and Teva’s Cinqair/Cinqaero, both who are approved worldwide.

Here are the details:

  • Buying all outstanding shares and assets was a deal worth over $75 million ($80 million) if all regulatory and commercial milestones are hit. 
  • Chiesi will add an experimental oral treatment for severe eosinophilic asthma currently in Phase 2, along with a “back-up candidate” coming out of a Phase 1 safety study. 
  • A report done by Visiongain states that the global asthma and COPD market could be worth more than $33 billion in 2016.
  • Around 40% of asthma patients are affected by Eosinophilic Asthma.

Related Articles:

How Loneliness is Linked to Alzheimer’s Disease

Plasmids Shown to Play Key Role in Spread of Antibiotic Resistance

 

 

 

SHARE IT
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email